The aim of this study is Perform a comparative analysis between clinical trials and patent families about leprosy worldwide in the last 20 years, using three technological aspects: diagnosis, drug/treatment and vaccine. A prospecting search in patent bank was conducted in the ORBIT Intelligence system, from Questel company. The search strategies utilized were based on ORBIT system, for each of the technological aspects established in the study (diagnosis, drug/treatment and vaccine). Clinical trials prospecting process was performed using simulations by WHO International Clinical Trials Registry Platform (ICTRP). Searching was carried out following a step-by step provided by the platform. A twenty-year time cut was adopted to harmonize the comparative analysis between patent and clinical trials recovered. Seventy-one clinical trials (11 for diagnosis, 54 for drug and 6 for vaccine) and 3323 patent families (790 for diagnosis, 1515 for drug and 1018 for vaccine) were identified, both distributed into 58 institutions and 21 countries. Through quantitative and qualitative analysis, a pattern of similarity was observed between institutions sponsoring clinical trials and holders of patent families, mainly related to years of registration and unionist priority filing, countries where clinical trials were performed and countries of unionist priority for patent families, phases of clinical trials and legal status of filed patent families. In summary, it is suggested that new public policies should be created to encourage synergy between clinical trials and patents, in order to induce a safe path to technological independence and, accordingly, a better performance in the struggle against leprosy in Brazil.
The work presents the analysis and synthesis of patent families about leprosy worldwide in the last 20 years. Three technological aspects were defined for the study of both portfolios, thus defined: diagnostic, drug/treatment and vaccine. Three thousand and three hundred twenty-three (3323) patent families were identified (790 for diagnostic, 1515 for drug and 1018 for vaccine). Fifty-eight (58) patent holders were identified and analyzed, with the most expressive portfolio of patent families, distributed in 13 countries. For the recovery of patent families, the ORBIT Intelligence® system from QUESTEL® was used. Using quantitative and qualitative analysis and synthesis, the patterns of five strategic indicators on the global patent scenario about leprosy were observed, namely: holders of patent families; the years of filing for unionist priority for patent families; countries of unionist priority for patent families; the legal status of filed patent families; and the legal status of patent families by country of protection. It is suggested that new public policies be created to encourage synergy between patent families and the social determinants of neglected populations, in order to induce a safe path to technological independence and better performance in the fight against leprosy in the Brazil.
Resumo -O presente trabalho apresenta a análise e a síntese de documentos de patentes sobre tuberculose (TB) depositados no Brasil. Breves conjecturas preliminares são elaboradas a partir da comparação entre os depósitos de 19 escritórios regionais (18 países e o EPO) e o Brasil. Apesar de o Brasil ser o primeiro em nacionalidade dos depositantes, nos demais indicadores seu desempenho é frágil. Foram recuperados 159 documentos de patentes, com 3 patentes concedidas, porém somente uma patente ainda em vigor e de titularidade de empresa privada dos EUA. Diante do avanço crescente da tuberculose no cenário mundial, acredita-se fortemente que o investimento no desenvolvimento de soluções tecnológicas, como patentes de combate a TB, se reveste de importância singular e estratégica, sobretudo para documentos de "prioridade", "nacionalidade" e "titularidade" brasileiras. A abordagem e o tratamento estatístico, quantitativo e qualitativo, aliados a uma hermenêutica reflexiva apresentados no documento em tela destina-se a ser um instrumento concreto para subsidiar ações que culminem em políticas públicas mais adequadas ao combate à tuberculose, por meio de um portfólio de patentes de brasileiros contra TB. Palavras-chave -patente, tuberculose, doença negligenciada.Abstract -This paper presents the analysis and synthesis of tuberculosis (TB) patent documents deposited in Brazil. Brief preliminary conjectures are drawn from the comparison between the deposits of 19 regional offices (18 countries and the EPO) and Brazil. Even though Brazil is the first in nationality of depositors in other indicators performance is fragile. 159 patent documents were recovered, with 3 patents granted, but only a patent is still valid and US private company. Faced with the growing advance of tuberculosis on the world stage, we believe strongly that investing in the development of technological solutions such as TB fight patent is of singular and strategic importance, especially for documents "priority", "nationality" and "ownership" brazilian. The approach and the statistical analysis, quantitative and qualitative, combined with a reflective hermeneutics presented on this document intended to be a practical tool to support actions that culminate in more appropriate public policies to combat tuberculosis through a portfolio of brazilian patent against TB. Keywords -patent, tuberculosis, neglected disease. I. INTRODUÇÃODiante do panorama mundial e nacional sobre o avanço da tuberculose, o presente trabalho destina-se a propor e iniciar um breve levantamento, análise e síntese sobre o cenário patentário sobre tuberculose no Brasil. Para tal, se faz necessário o levantamento do estado da técnica disponível no banco de patentes do INPI que aborde a tuberculose. O texto em tela não pretende ser totalmente abrangente no escopo, nem tão pouco
desenvolvimento de um sistema informacional de apoio da decisão, por meio da computação natural, para análise, modelagem e uso estratégico de indicadores de patentes em nanociências.
Introduction: The work presents a comparative analysis between clinical trials and patent families on COVID-19 associated with CRISPR-Cas, ACE2 and Spike worldwide. Methods: From a total of 7815 clinical trials dedicated to COVID-19, 238 clinical trials related to CRISPR-Cas, ACE2 and Spike were identified, and 112 patent families. For the recovery of clinical trials and patent families, the ICTRP® platform of the World Health Organization, the ORBIT INTELLIGENCE® system from Questel® and the INPI COVID-19 Observatory were used, respectively. Results: Through quantitative and qualitative analysis and synthesis, a pattern of insignificant similarity was observed between the institutions that sponsor clinical trials and holders of patent families, among other correlated indicators. Conclusions: In summary, it is suggested that new public policies be created to encourage synergy between clinical trials and patents, both national, in order to induce a safe path to technological independence and, consequently, better performance in combating COVID-19 associated with CRISPR-Cas, ACE2 and Spike in Brazil.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.